ATC Group: C08CA05 Nifedipine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C08CA05 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C08 Calcium channel blockers
3 C08C Selective calcium channel blockers with mainly vascular effects
4 C08CA Dihydropyridine derivatives
5 C08CA05 Nifedipine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 30 mg
PAREN - Parenteral 30 mg

Active ingredients in C08CA05

Active Ingredient Description
Nifedipine

Nifedipine is a calcium antagonist of the 1,4-dihydropyridine type. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell. As a specific and potent calcium antagonist, nifedipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. The main action of nifedipine is to relax arterial smooth muscle, both in the coronary and peripheral circulation. Nifedipine Tablets are formulated to achieve controlled delivery of nifedipine in a release profile sufficient to enable once-daily administration to be effective in clinical use.

Related product monographs

Title Information Source Document Type  
ADALAT Tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
FENAMON SR Modified release tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
NIDEF Prolonged release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NIFELAT Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
PROCARDIA Capsule FDA, National Drug Code (US) MPI, US: SPL/Old
PROCARDIA XL Extended release tablet FDA, National Drug Code (US) MPI, US: SPL/Old

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Cyprus (CY)

Ecuador (EC)

France (FR)

Ireland (IE)

Japan (JP)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Romania (RO)

Spain (ES)

Tunisia (TN)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.